GE HealthCare Technologies Inc（GEHC）の決算・業績分析
GE HealthCare Technologies Incの2025年有価証券報告書をAI分析。売上高$20.6B(+4.8%)。営業利益$2.8B。Health Care。
目次
GE HealthCare Technologies Incの2025年度 業績サマリー
GE HealthCare Technologies Inc（証券コード: GEHC）の2025年度決算・業績分析。売上高は$20.6B（前年比+4.8%）。営業利益は$2.8B（前年比+5.3%）。純利益は$2.1B（前年比+4.6%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
GE HealthCare Technologies Incの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- GEHC reported FY2024 revenue of $18.3B (+4.3% YoY) but saw operating income decline by 9.8% YoY to $2.5B (XBRL).
- Net income fell 14.7% YoY to $1.9B, while EBITDA margin remained stable at 15.0% (XBRL).
- Net debt stood at $5.9B (2.2x EBITDA), with cash reserves of $2.5B (XBRL).
- ROE of 26.9% highlights strong equity returns despite a 3.53x debt-to-equity ratio (XBRL).
GE HealthCare Technologies Incの売上高変化の要因
- •FY2024 revenue grew 4.3% YoY to $18.3B, with a 5-year CAGR of 5.4% (XBRL). Historical data shows revenue increasing from $17.6B (FY2023) to $19.6B (FY2025) (XBRL). Segment-specific revenue details are not quantified in the XBRL data but are disclosed in Note 4 of the 10-K (10-K). Growth drivers include expansion in AI-enabled services and digital solutions, though operating income declined 9.8% YoY to $2.5B (XBRL).
GE HealthCare Technologies Incの営業利益変化の要因
- •Gross margin remained robust at 39.1%, but operating margin fell to 13.8% (-9.8% YoY) and net margin to 10.4% (-14.7% YoY) (XBRL). EBITDA of $2.8B (15.0% margin) reflects cost management despite declining operating income. The 5-year CAGR for operating income is -6.7%, and net income CAGR is -16.5% (XBRL).
GE HealthCare Technologies Incの事業リスクと対応
Competitive markets and industry disruption could reduce pricing or market share (10-K).
Geopolitical instability and economic uncertainty may harm operations and supply chains (10-K).
Payer cost controls may reduce reimbursements or demand for products (10-K).
Challenges in deploying AI and cloud technologies could hinder adoption (10-K).
Supply chain disruptions may delay deliveries and increase costs (10-K).
GE HealthCare Technologies Incの事業内容
GEHC operates as a global healthcare solutions provider, generating revenue through medical devices, consumables, service capabilities, and digital solutions (10-K). Key segments include Imaging (molecular imaging, CT, MR, X-ray), Advanced Visualization Solutions (AVS, ultrasound, image-guided therapies), Patient Care Solutions (patient monitoring systems), and Pharmaceutical Diagnostics (PDx, diagnostic tools for pharmaceutical research) (10-K). The company serves healthcare providers, researchers, and institutions across 160+ countries with no significant customer concentration (10-K). Competitive advantages include 125 years of industry experience, AI-enabled solutions, and a lean operational culture (10-K).
GE HealthCare Technologies IncのAI業績分析レポート（2024年度）
GE HealthCare Technologies Inc. (GEHC) FY2024 Annual Report Analysis
Highlights
Business Overview
GEHC generates revenue from medical devices, consumables, services, and digital solutions (10-K). Key segments include Imaging (molecular imaging, CT, MR, X-ray), Advanced Visualization Solutions (AVS, ultrasound), Patient Care Solutions (patient monitoring), and Pharmaceutical Diagnostics (PDx, diagnostic tools) (10-K). The company serves healthcare providers and institutions globally with no significant customer concentration (10-K). Competitive advantages include 125 years of experience, AI-enabled solutions, and a lean operational culture (10-K).
Revenue Analysis
FY2024 revenue grew 4.3% YoY to $18.3B, with a 5-year CAGR of 5.4% (XBRL). Historical data shows revenue increasing from $17.6B (FY2023) to $19.6B (FY2025) (XBRL). Segment-specific revenue details are not quantified in the XBRL data but are disclosed in Note 4 of the 10-K (10-K). Operating income declined 9.8% YoY to $2.5B, with a 5-year CAGR of -6.7% (XBRL).
Profitability Analysis
Gross margin of 39.1% remained strong, but operating margin fell to 13.8% (-9.8% YoY) and net margin to 10.4% (-14.7% YoY) (XBRL). EBITDA of $2.8B (15.0% margin) reflects cost management despite declining operating income. Net income CAGR over 5 years is -16.5% (XBRL).
Balance Sheet Analysis
Equity ratio declined to 22.0%, with total equity falling from $9.4B (FY2023) to $7.1B (FY2024) (XBRL). Long-term debt rose to $8.4B, resulting in a net debt of $5.9B (2.2x EBITDA). Current ratio of 1.05x indicates tight liquidity, with cash reserves of $2.5B (XBRL). Total assets grew to $32.5B (FY2024) from $27.5B (FY2023) (XBRL).
Cash Flow Analysis
Operating cash flow increased 31.3% YoY to $2.1B, while free cash flow (FCF) was $1.7B (XBRL). Investing cash flow was -$398M, and financing cash flow was -$822M, with no dividends paid (XBRL). Capital expenditures are not quantified in the XBRL data but may be detailed in Note 9 of the 10-K (10-K).
Working Capital Analysis
N/A
Risks
Outlook
N/A
Health Careの企業一覧
GE HealthCare Technologies Incと同じ「Health Care」セクターの企業